OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa

Inclusion Criteria: * Agreement to come to the clinic for all follow-up evaluations * Provision of informed consent and assent (as appropriate) * Residency within approximately 30 km of the study clinic * Negative blood smear for malaria (all sites) * For Children and adolescents living with HIV * Confirmed HIV infection * On DTG-based regimen for ≥14 days * For HIV-uninfected children - documentation of HIV-negative status by at least 1 assay Exclusion Criteria: * Significant comorbidities such as malignancy, active TB, chronic/active hepatitis B/C, diabetes, severe acute malnutrition, mitochondrial disorders * Receipt of known CYP interacting drugs at enrolment (except HAART) - see list of disallowed medications * Anemia defined by hemocue (Hb \< 7.0) at the time of enrolment * Signs of uncomplicated or severe malaria at the time of enrollment * Prior intolerance to AL or AS-AQ (for those in Busia only) * Pregnancy at enrolment (testing done at enrollment for all those of child-bearing age) * Concurrent enrolment in another research study